End Of Schultz Era Looms For Teva

CEO Kåre Schultz Unlikely To Renew Contract Past November 2023, Company Confirms

 
• By David Wallace
  
Kare Schultz
Kåre Schultz has been president and CEO of Teva since late 2017 • Source: Teva
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Leadership

More from Generics Bulletin